Every 10-Q that Aura Biosciences, Inc. (AURA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AURA filings page.
Aura Biosciences, Inc. reported continued clinical-stage investment with no product revenue and a larger loss for the period. For the three months ended June 30, 2026, total operating expenses were $48.1 million, driving a net loss of $45.6 million versus $27.0 million a year earlier. For the six months ended June 30, 2026, the net loss was $79.3 million compared with $54.5 million in 2025, reflecting higher research and development and general and administrative spending.
Liquidity strengthened after a May 2026 follow-on offering that raised approximately $280.8 million in net proceeds, partly used to repurchase 6,922,870 shares from a major holder. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $323.8 million, and the company expects these resources to fund operations for at least 12 months from the financial statement issuance date.
Belzupacap sarotalocan (bel-sar) remains the sole product candidate, in a pivotal Phase 3 trial for early choroidal melanoma with topline data not expected until the second half of 2027, and in additional ocular and urologic oncology programs. Aura highlights an interim signal in non-muscle invasive bladder cancer but plans to minimize spending on that program while refocusing resources on ocular oncology, supported by an August 2026 restructuring that includes about a 20% workforce reduction.
Aura Biosciences reported a larger quarterly loss as it ramps up late-stage development of its lead cancer drug bel-sar. For the three months ended March 31, 2026, the company recorded a net loss of $33.7 million, compared with $27.5 million a year earlier, driven mainly by higher research and development and general and administrative expenses.
Cash, cash equivalents and marketable securities totaled $114.7 million at March 31, 2026. After quarter-end, Aura completed a 2026 follow-on equity offering, raising net proceeds of about $280.8 million and using roughly $39.0 million to repurchase 6,922,870 shares from a major stockholder, steps that management believes extend its funding runway into the second half of 2028 and alleviate prior going concern uncertainty.
Aura Biosciences reported Q3 2025 results, highlighting ongoing late-stage development of bel-sar and continued investment in R&D. Net loss was $26.1 million (basic and diluted loss per share $0.40) on total operating expenses of $27.9 million, driven by research and development of $22.2 million and general and administrative of $5.7 million. Other income was $1.8 million.
Liquidity remained solid with $47.6 million in cash and cash equivalents and $114.3 million in marketable securities as of September 30, 2025. Total assets were $190.0 million and stockholders’ equity was $156.7 million. Shares outstanding were 62,985,569 at quarter-end; 63,503,269 as of November 10, 2025.
Year to date, operating cash use was $64.3 million, offset by financing inflows including the May 2025 follow-on that raised approximately $69.9 million net (common shares, pre-funded warrants, and accompanying warrants) and Q3 activity under the ATM. Management expects current cash and marketable securities to fund operations for at least 12 months from issuance. The Phase 3 CoMpass trial in early choroidal melanoma is ongoing, with enrollment targeted for 2026 and a 15‑month primary endpoint readout planned for Q4 2027.
Aura Biosciences is a clinical-stage biotech developing Virus-Like Drug Conjugates; its lead candidate bel-sar is in a global Phase 3 CoMpass trial for early choroidal melanoma and in trials for choroidal metastases and bladder cancer. In a Phase 2 cohort of Phase 3-eligible patients, bel-sar achieved an 80% tumor control rate (8 of 10) and 90% visual acuity preservation, with a favorable safety profile; the company reported positive Phase 1 NMIBC data in March 2025 and is advancing a Phase 1b/2 NMIBC program.
On the balance sheet, Aura held $107.4M cash and $69.9M marketable securities (total $177.3M) as of June 30, 2025, received $69.9M net proceeds from a May 16, 2025 follow-on offering, and stated this funding is expected to support operations into the first half of 2027. The company reported a $54.5M net loss for the six months ended June 30, 2025 and an accumulated deficit of $428.7M, reflecting continued high R&D investment.